Carminomycin (NSC-180024): a phase I study.

Carminomycin is a new anthracycline derivative. In this phase I trial, the drug was given i.v. every 3-4 weeks to 19 patients with solid tumors. Thirty-five courses of therapy were given. Leucopenia was dose-related and dose-limiting with a steep dose-effect relationship. Leucopenia appeared to be exacerbated in patients with low performance status and massive liver involvement. Thrombocytopenia was negligible. Mild to moderate alopecia was encountered in less than one-half of the patients. Vomiting and stomatitis were not seen. Transient electrocardiographic changes could be documented in two patients. Drug-induced congestive heart failure was not observed but full evaluation of the cardiac effect of carminomycin requires more prolonged treatments and larger accrual of patients. Doses of 20 mg/m22 repeated every 3 weeks can be recommended for phase II trials with carminomycin in good-risk patients. Relative to leucopenia, other acute toxic manifestations appear to be of minor clinical significance which makes this new anthracycline attractive for further investigation. © 1980.
Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
info:eu-repo/semantics/published